Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2026)

Contineum Therapeutics' Total Current Liabilities history runs 4 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 25.61% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 25.61% decrease from a year earlier, with the FY2025 full-year figure at $9.7 million, down 2.31% from the prior year.
• Total Current Liabilities fell to $6.7 million in Q1 2026 per CTNM's latest filing, from $9.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $10.0 million in Q4 2024 and bottomed at $3.7 million in Q2 2024.
• The 4-year median for Total Current Liabilities is $6.5 million (2025), against an average of $7.0 million.
• Across the five-year window, Total Current Liabilities surged 92.94% in 2025 and retreated 25.61% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $5.5 million in 2023, then soared by 81.87% to $10.0 million in 2024, then fell by 2.31% to $9.7 million in 2025, then plunged by 31.68% to $6.7 million in 2026.
• Per Business Quant, the three latest CTNM Total Current Liabilities figures stand at $6.7 million (Q1 2026), $9.7 million (Q4 2025), and $6.4 million (Q3 2025).